Related Experiment Video

Updated: May 3, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

5.7K

The structural basis of PI3K cancer mutations: from mechanism to therapy

Shujuan Liu1, Stefan Knapp, Ahmed Ashour Ahmed

  • 1Authors' Affiliations: Weatherall Institute of Molecular Medicine, University of Oxford, Headington; Nuffield Department of Obstetrics and Gynaeoclogy, Women's Centre, John Radcliffe Hospital; Nuffield Department of Clinical Medicine, SGC, Oxford, United Kingdom; and Xijing Hospital, the Fourth Military Medical University, Shaanxi Province, China.

Cancer Research
|January 25, 2014
PubMed

Insights

The phosphoinositide 3-kinase (PI3K) p85α regulatory subunit plays a crucial role in cancer cell survival. Understanding its p110-independent functions is key for developing targeted cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Structural Biology

Background:

  • The phosphoinositide 3-kinase (PI3K) p85α-p110α complex is frequently altered in cancer.
  • Wild-type PI3K is essential for cancer progression, often through related pathway mutations.
  • Understanding PI3K mechanisms is vital for effective therapeutic strategies.

Purpose of the Study:

  • To review the structural, biochemical, and biologic mechanisms of p85α in cancer cell regulation.
  • To emphasize the role of p85α in cell survival, including p110-independent functions.
  • To highlight recent genetic alterations in cancer impacting the PI3K pathway.

Main Methods:

  • Review of recent structural data of the p85α/p110α complex.
  • Analysis of biochemical and biologic information on PI3K regulation.
  • Integration of recent genetic findings in cancer.

Main Results:

  • Recent structural data elucidate PI3K activation mechanisms and dimer regulation.
  • Evidence supports p110-independent functions of p85α in regulating cell survival.
  • Genetic alterations in cancer affecting PI3K are increasingly identified.

Conclusions:

  • p85α plays a significant role in regulating the cancer cell life cycle.
  • Targeting PI3K, a key driver, may be necessary for treating heterogeneous, late-stage tumors.
  • Further research into p85α functions can inform novel cancer treatment strategies.

More Related Videos

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.1K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
12.1K